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INTRODUCTION
Since the publication of a review of Antiretroviral
Resistance Testing in the September 2000
HEPP News,1 resistance testing has become an
important component of standard care for HIV -
infected patients. This is largely due to the wide-
spread availability of genotypic testing, as well
as increased access to both the virtual and stan-
dard phenotype tests. Additionally, the increas-
ing presence of resistance in both antiretroviral
(ARV) experienced and ARV naïve individuals,
combined with the availability of newer ARV
agents capable of overcoming drug resistance,
has fueled the need to assess for drug resis-
tance in patients being treated for HIV infection.
This article will provide an update on new devel-
opments in the area of HIV resistance and pro-
vide a guide to the implementation of resistance
testing in correctional settings.
PREVALENCE OF RESISTANCE
HIV resistance is increasing in the U.S.
Richman, et al.2 reported in a study in late 2001
on the prevalence of resistance in the United
States.  In using the HIV Cost and Service
Utilization Study database, 1,906 patients who
were on treatment (receiving antiretroviral thera-
py) between 1996 and 1999 were identified.  A
phenotypic resistance assay was done on 1,209
patients whose viral load was >500 copies/mm3.
Seventy eight percent (78%) had resistance to at
least one ARV agent, 50% had resistance pre-
sent in two classes of ARV agents, and 14% had
three-class, or multi-drug resistant HIV (MDR-
HIV). The majority of resistance was found in the
nucleoside reverse transcriptase inhibitor (NRTI)
class with lesser degrees in the protease
inhibitor (PI) and non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) classes, which may
have been related to the date of the study (PIs
and NRTIs were new when the study started).
This degree of resistance likely reflects incom-
plete adherence to therapy (see Figure 1). 
Equally disturbing is the increasing prevalence
of ARV resistance in drug-naïve people who are
recently HIV infected as first described by Little
et al. and subsequently confirmed by others.
Little et al.showed that 15% of acutely infected
(naïve) patients had genotypic mutations at the
time of their diagnosis. More importantly, these
mutations in the reverse transcriptase and pro-
tease genomes persisted up to 303 days in the
absence of ARV therapy3. Bennett et al.
described the prevalence of genotypic resis-
tance in a cohort of patients newly infected with
HIV between 1998 and 20004. Ten percent of
patients had NRTI resistance mutations, 4% had
PI mutations, and 3% had NNRTI mutations; and
4% had resistance mutations in two classes of
agents.  
WHEN TO USE 
RESISTANCE ASSAYS
Use of genotypic or phenotypic resistance
assays has been shown to improve response to
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Figure 1: Relationship Between Drug
Pressure and Amount of Drug-Resistant HIV
DRUG PRESSURE
Figure 1 represents the relationship between the
amount of drug pressure applied to HIV versus the
viral drug-resistance that develops. At the extreme
left of the curve, there is absolutely no drug pressure
applied to the virus, and thus the amount of viral
mutation that occurs and results in drug-resistant
virus is very low. As drug pressure increases, how-
ever, the virus must mutate and become drug-resis-
tant if it is to continue to "survive," or replicate. Drug-
resistant virus is most likely to occur when there is
enough drug pressure to select for drug-resistant
virus, but not enough to significantly suppress viral
replication (the star on the left side of the graph illus-
trates such a situation, for example, when patients
are not adherent to their medications).  At the far end
of the graph, there is again little drug-resistant virus
present because there is enough drug pressure to
significantly inhibit viral replication. This makes the
likelihood of a drug-resistant mutation small, as
there are so few copies of the virus being made at
any given time (this often occurs when a patient is
on successful ARV treatment).
*
rescue therapy in patients failing therapy.5,6
Combined with the above data, the current
recommendation that resistance testing be
performed in patients failing therapy or with
incomplete viral suppression is warranted.
And, although not yet generally recom-
mended, the epidemiological data
described above support the use of geno-
typic testing in recently infected patients for
up to a year after their infection.  However,
clinical studies assessing this strategy
have not been done (see HEPPigram,
page 7 for guidance).
DEFINING RESISTANCE
Resistance is best defined as reduced sus-
ceptibility of HIV to a specific ARV agent.
As a result, resistance is not an all or none
phenomenon. This relative reduction in
susceptibility is best displayed through the
use of phenotypic testing. The phenotypic
assay reports the fold-increase in drug con-
centration needed to inhibit 50% of viral
replication (IC50). The threshold defining
reduced susceptibility for the nucleoside
and non-nucleoside reverse transcriptase
inhibitors (NRTIs and NNRTIs) is drug-spe-
cific. For example, a greater than 1.6-fold
increase in the IC50 for stavudine confers
resistance, whereas for tenofovir a 3.8-fold
increase is necessary to confer resistance.  
For non-ritonavir enhanced protease
inhibitors (PIs), a greater than 2.5 - 4 fold
increase in the IC50 (depending on the
assay used) usually signifies an intermedi-
ate reduction in susceptibility, whereas a
greater than 10-fold increase is required to
confer complete resistance. With the intro-
duction of co-formulated lopinavir/ritonavir
(Kaletra), the standard PI thresholds no
longer apply. The small amount of ritonavir
in Kaletra leads to a large increase in
lopinavir drug levels. Specifically, the
lopinavir trough concentration (Cmin) greatly
exceeds the IC50 in both wild-type and drug
resistant HIV strains. Therefore the so-
called inhibitory quotient (Cmin/ IC50) for
lopinavir is quite large.7 Patients who failed
three or more prior PI-containing regimens
still responded to rescue therapy contain-
ing lopinavir/ritonavir as long as the fold-
change in the IC50 was less than 40.
Specific thresholds have not yet been
defined for other ritonavir-enhanced regi-
mens such as ritonavir plus indinavir,
amprenavir, or saquinavir.
One last concept specific to phenotypic
resistance testing is hypersusceptibility.
Hypersusceptibility exists when there is a
decrease in the amount of drug needed to
inhibit viral replication. This is most com-
monly seen with the NNRTIs in the setting
of significant prior NRTI use, but has also
been seen with amprenavir. Clinically,
Shulman et al has shown an enhanced
anti-viral response in the presence of
hypersusceptibility to efavirenz.8
In contrast to phenotypic testing, genotypic
testing defines resistance based on the
number of known resistance-conferring
mutations present at the time of testing.
The threshold differs for each drug
because resistance is conferred by differ-
ent mutational patterns. Each genotypic
resistance-testing manufacturer sets up
their own rules by which they interpret
whether the mutations present are likely to
confer reduced susceptibility. This can lead
to significant differences in interpretations
between testing kits, as well as confusion
amongst clinicians inexperienced in inter-
preting genotypic resistance test results.9
Therefore, it is recommended that HIV
experts assist with interpreting genotypic
testing (see Table 1 for a comparison of
genotypic and phenotypic testing).
Genotypic testing has led to the recently
appreciated concept of NRTI class cross-
resistance. Although the infrequently (1-
3%) seen Q151M and T69S insertion muta-
tions have been known to confer resistance
across most of the NRTI class, work done
by Whitcomb et al.at Virologic has shown
that mutations previously associated with
just zidovudine resistance actually confer
resistance to all the NRTIs.10 These spe-
cific codon mutations-41, 67, 70, 210, 215,
and 219-referred to as thymidine or nucle-
oside analogue mutations (TAMs or NAMs)
cause varying degrees of resistance to all
the nucleoside and nucleotide analogues
(see HIV101, page 5). The more mutations
present, the broader the resistance.
Despite all the data that may be derived
about a patient's virus from the use of resis-
tance assays, additional intricacies may
limit their utility.  First, discordance between
genotypic and phenotypic testing exists.
Parkin, et al. evaluated 200 patient
samples with both testing modalities and
found one-drug discordance in 75% and
four-drug discordance in 22% of samples.11
Additionally, these in vitroassays may not
translate into in vivoresponse. The rea-
sons for this are multifactorial and include
non-adherence, interpatient variability in
absorption and metabolism of the agents
(variability in therapeutic drug levels, see
TDM below), and adverse drug-drug inter-
actions. Finally, it should be understood
that resistance test results reflect the pres-
sure exerted by the current regimen on the
virus. So if a patient who had previously
developed the M184V (amino acid M
replaced by amino acid V at position 184)
mutation while on lamivudine is not taking it
at the time resistance testing is repeated,
this mutation may not be prevalent in ade-
quate amounts to be detected (it may be
present in an "archived" form in resting T
cells). However if the patient is then started
on a lamivudine-containing regimen that is
not fully suppressive, the mutation will
reappear and lead to virologic failure.
Therefore, clinicians must utilize all avail-
able resistance test results and information
about prior ARV therapy when planning
rescue therapy. 
EVOLVING RESISTANCE IN
THE FACE OF LOW-LEVEL
VIREMIA
Several years ago, Deeks et al. in San
Francisco described their cohort of patients
who had previously been undetectable on
PI-based ARV therapy but subsequently
had viral breakthrough. In this group,
despite persistent viremia while on their
failing regimen, most remained immunolog-
ically and clinically stable for many years.12
This study led many clinicians to maintain
patients on their failing regimens. Coakley
2
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Table 1: Advantages and Disadvantages of Genotypic and Phenotypic Testing17
ADVANTAGES
Genotypic Assays
w Less expensive ($300 to $480/test)
w Short turn-around (1-2 weeks)
w May detect presence of resistance muta-
tions before they have affected phenotypic
resistance
Phenotypic Assays
w Interpretation more analogous to resis-
tance testing of bacteria
w Asseses 3-dimensional molecule, includ-
ing mutations and mutational interactions
w Reproducibility is good
w Advantage over genotype when multiple
mutations exist
DISADVANTAGES
w Detect resistance only in dominant
species of virus (>20% of patient's iso-
l tes)
w Interpretation requires understanding
and knowledge of mutational changes (i.e.
expertise)
w Technician experience may influence
results
w May show discrepancy with phenotype
w Require viral load> 1000 copies/mL
w More expensive ($800-$1000)
w Longer delay in reporting (2-3 weeks)
w Thresholds to define susceptibility to
drug are arbitrary and non-standardized;
do not always reflect achievable drug 
concentrations
w Detect resistance only in dominant
species (>20% of patient's isolates)
w Require viral load >500-1000 copies/mL
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Dear Colleagues:
As I begin my tenth year providing healthcare to the incarcerated, I've taken some time to
reflect on the past decade and the successes and failures I've experienced in our efforts to
provide quality treatment to those living behind bars with HIV, hepatitis, and other serious
medical conditions.
Like all perfectionists, I tend to dwell on the deficiencies…staffing problems, budgetary
woes, and all of my yet-to-be accomplished goals in correctional healthcare.  Sometimes I
need to be reminded of how far we have come in improving the life expectancies and qual-
ity of life of our HIV-infected patients.
In April of this year I joined three other physicians on a medical mission to Benin City in Edo
state, Nigeria.  Our goals included providing an intensive HIV educational program for
healthcare providers, and attempting to lay the foundation for an HIV treatment program.
We met some intensely dedicated individuals struggling against all odds to provide basic
healthcare in the absence of running water, reliable electricity, medications, gloves, basic
supplies, and, oft times, even a salary.  
I returned saddened by what I saw, but also inspired by my Nigerian colleagues and remind-
ed of how blessed we are to have the basic tools to provide our patients treatment for what
is in many parts of the world still an untreatable disease.
This month, Dr. Peter Piliero updates us on the use of HIV genotype and phenotype analy-
sis.  This month's HEPPigram provides an approach to the application of HIV resistance
testing. After reading this issue providers should be familiar with the issues of HIV resis-
tance and genotype and phenotype analysis. 
My kudos to all of you who continue to struggle to improve the quality of healthcare for the
incarcerated. You all contribute mightily, not only to your patients but also to this nation's
public health.
Sincerely,
Joseph Bick
Letter from the Editor
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4et al. recently reported on a cohort of
patients who were receiving similar ARV
therapy and who had rebounded with a viral
load less than 1000 copies/mm3.13 These
patients had detectable viremia for a mean
of 22 months during which their CD4 count
rose 97 cells/mm3 and viral load rose 61
copies/mm3. Forty patients had a genotype
obtained which revealed that 90% had resis-
tance to one or more of the ARVs they were
taking. Six of seven patients whose viral
load rose above 1000 copies/mm3 had resis-
tance to all three agents compared with only
nine of 33 whose viral load remained less
than 1000 copies/mm3. Therefore, despite
the lack of clinical and immunologic damage
during low level viremia, viral evolution is
ongoing and is likely to be clinically signifi-
cant when rescue therapy is attempted.
Thus, maintaining patients on failing regi-
mens may be detrimental.
COMBINING RESISTANCE
TESTING WITH OTHER
MODALITIES
Newer testing modalities such as therapeu-
tic drug monitoring (TDM) and viral fitness
assays are not yet widely available, but are
being studied in patients taking ARV thera-
py. When available, these will most likely be
utilized in patients failing treatment and will
therefore be combined with resistance assay
results to further assist in the management
of this expanding population. 
THERAPEUTIC DRUG 
MONITORING (TDM)
TDM involves measuring plasma drug con-
centrations.  The trough (or Cmin) is the con-
centration of drug just prior to administration
of the next dose. Protease inhibitor trough
levels have been linked to efficacy.14 This
data, in conjunction with the unpredictable
pharmacokinetic profile of the protease
inhibitors, has led to clinical studies examin-
ing the role of TDM. Burger, t al.looked at
the use of TDM with nelfinavir based regi-
mens and found that use of TDM led to
increasing the nelfinavir dose to achieve a
better Cminand virologic outcome.
15 As men-
tioned earlier, ritonavir-boosted PIs achieve
higher Cmin values and when TDM is readily
available it will likely be combined with phe-
notypic data to adjust dosing in individuals to
overcome resistance.  
VIRAL FITNESS
Viral fitness is the ability of the virus to repli-
cate, infect, and kill T cells. Fitness varies
between wild type and resistant strains. The
acquisition of resistance mutations often
leads to a period of decreased fitness, which
in turn has been associated with prolonged
immunologic stability in the setting of viro-
logic failure.16 A fitness assay might be uti-
lized to determine which patterns of resis-
tance are less damaging. Clinicians can now
begin receiving this type of information with
a new replication assay, Replication
Capacity (Virologic),  that is now provided
with Virologic's phenotype assays.
CLINICAL APPLICATION OF
RESISTANCE TESTING
The use of resistance testing is illustrated by
the following clinical case. A 38 year-old
African-American inmate presented for HIV
specialty care in March 2000.  He had a his-
tory of HIV infection since 1996 but was
asymptomatic and had a history of hepatitis
C.  In March 2000 he had a CD4 count of
375 cells/mm3 (15%) and a viral load of 736
copies. He was taking stavudine, lamivu-
dine, and efavirenz since July 1999 but
notably each drug had been started sequen-
tially over a 2-year period. He had also
received zidovudine, indinavir, and nelfinavir
in the past.  The decision at this time was to
continue his current ARV given his overall
stability.
He remained clinically stable on this regimen
for the next 16 months and his CD4 count
and viral load ranged from 324-414
cells/mm3 and <400-1571 copies/mm3
respectively. In August 2001 his viral load
peaked at 3,080 copies/mm3 with a concur-
rent CD4 count of 399 (18%). A genotype
was ordered and showed mutations at the
following positions: 1) NRTI: 184, 2) NNRTI:
103, and 3) PI: 30, 63, 77, and 88 (see
HIV101, page 5). These mutations were
interpreted as conferring resistance to
lamivudine, all the NNRTIs, and nelfinavir.  
Due to the increase in his viral load and clear
accumulation of resistance mutations, a
change in ARV to lopinavir/ritonavir
(Kaletra), stavudine (D4T or Zerit), didano-
sine (ddI, Videx), and abacavir (ABC,
Ziagen) was made. Viral load two and six
months later were 703 and <400
copies/mm3 respectively, and his CD4
remained stable at 336 (18%).  He was sub-
sequently paroled on stable ARV.
This case illustrates several important clini-
cal issues regarding HIV resistance. First,
sequential changes in ARV agents rather
than changing the entire regimen when fail-
ing therapy will lead to incomplete suppres-
sion. This patient's current ARV regimen
was not started simultaneously and the addi-
tion of agents with a low genetic barrier to
resistance (due to the low number of muta-
tions required to develop resistance, see
HIV 101), ie. lamivudine and efavirenz, while
there is incomplete suppression will lead to
the development of resistance to these
agents. Second, despite clinical and
immunologic stability, viral evolution and
accumulation of mutations will occur in the
setting of incomplete viral suppression as
was shown by Coakley et al. Any replication,
even at low levels as in this patient, will allow
the virus to evolve and develop mutations
that sabotage the success of the regimen.
Finally, resistance testing in the setting of
virologic failure provides important informa-
tion that leads to a greater likelihood of suc-
cessful rescue therapy.  As has been exhib-
ited in several prospective studies, use of
resistance assays allows clinicians to
choose an ARV regimen with more active
agents and therefore have a higher chance
of suppressing viral replication.
CONCLUSION
Because of the significant prevalence of
drug-resistant virus in both treatment-experi-
enced and treatment-naïve patients, resis-
tance testing has become an important com-
ponent of the care of HIV-infected patients. It
is important to keep in mind that patients
w th persistent low-level viremia continue to
evolve drug-resistant viruses. Genotype and
phenotype testing have been shown to
increase patient response to rescue thera-
pies in treatment-experienced individuals.
The benefits of genotyping and phenotyping
increase when the test results are used in
conjunction with the consultation of an HIV
expert to develop a treatment plan.
Therapeutic drug-monitoring may play a
greater role in the future, especially with
drugs that have a low trough (Cmin) level.
GLOSSARY OF TERMS17
Genotypic analysis involves: 1) amplica-
tion of the reverse transcriptase (RT) gene,
protease (Pr) gene, or both by RT PCR; 2)
DNA sequencing of amplicons generated for
the dominant species (mutations are limited
to those present in >20% of plasma virions);
3) reporting of mutations for each gene
using a letter-number-letter standard, in
which the first letter indicates the amino acid
at the designated codon with wild type virus,
the number is the codon, and the second let-
ter indicates the amino acid substituted in
the mutation (See HIV101, page 5 for a list
of amino acid single letter abbreviations).
Updated information on resistance testing
can be obtained at http://hiv-web.lanl.gov.
Genotypic assays include GeneSeq
(Virologic), Truegene (Visible Genetics) and
GenoSURE (LabCorp).
Phenotypic analysis involves insertion of
the RT and protease genes from the
patient's strain into a backbone laboratory
clone by cloning or recombination.
Replication is monitored at various drug con-
centrations and compared to a reference
wild type virus. This assay is comparable to
conventional in vitro tests of antimicrobial
sensitivity, in which the microbe is grown in
serial dilutions of antiviral agents. Results
are reported as the IC50 for the test strain rel-
ative to that of a reference or wild type strain.
The interpretation was previously based on
a fixed ratio such as 4x to define resistance,
Update on HIV Resistance
Testing... (continued from page 2)
Continued on page 6
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5Understanding HIV Drug-Resistance Mutations
A
C
D
E
F
G
H
I
K
L
M
N
P
Q
R
S 
T
V
W
Y
Alanine
Cytosine
Aspartic acid
Glutamic acid
Phenylalanine
Glycine
Histidine
Isoleucine
Lysine
Leucine
Methionine
Asparagine
Proline
Glutamine
Arginine
Serine
Threonine
Valine
Tryptophan
Tyrosine
ANTIRETROVIRAL DRUG
Zidovudine (AZT)
Lamivudine (3TC)
Zalcitabine (ddC)
Stavudine (d4T)
Abacavir (ABC)
Multinucleoside resistance- A
Multinuceloside resistance-B
Nevirapine (NVP)
Efavirenz (EFV)
POSITIONS OF CODON MUTATIONS
41,67,70,210,215,219
184
65,69,184
75
41,65,67,70,74,115, 184,210,215,219
62,75,77,116,151
41,62,67,69 (insertion),70,210,215,
219
100,103,106,108,181, 188,190,230
100,103,108,188L,190, 225,230
COMMENT
Mutations are "TAMs*"- reduce susceptibility
to AZT, d4T, ABC
184- high level 3TC resistance, increases
activity of d4T, AZT, and tenofovir
D4T selects for TAMs, which reduce sensitivity
to d4T, AZT, ABC. The 75 mutation is rarely
seen in vivo. Instead, mutations listed for AZT
should probably be viewed as primary and
secondary d4T mutations, as well.
Resistance depends on the number of TAMs.
Virus with M184V and 3 or more TAMs is gen-
erally resistant to ABC. ABC selects for muta-
tions that may confer cross-resistance to 3TC
and ddI.
Occurs with or without TAMs. Confers resis-
tance to all NRTIs, but NOT tenofovir
Requires TAMs. Confers resistance to all
NRTIs AND tenofovir, but NOT DAPD.
Y181C is favored mutation with NVP, unless
combined with AZT, then K103N is favored
Sensitive in vitro to 181 mutants; resistance
with 188L but not 188C or 188H
Drug-resistance mutations are named according to a certain formula: the first letter represents the amino acid present in the
wild type virus (see Table 1). This is followed by a number that indicates the position of the amino acid that has mutated.  The
last letter indicates the new amino acid present at that position.  For example, M184V, a common reverse transcriptase muta-
tion, means that the methionine at position 184 in the wild type virus has been replaced by a valine at position 184 in the
mutated virus.
Sample Patient Genotype Results
HIV, Genotype
06/03/02  Mutations detected on reverse transcriptase gene: A98S, K103N, M184V
Mutations detected on protease gene: L63P
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and Nucleotide RTIs
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
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Single-Letter Codes Used for Amino Acids
Table 1. Common Drug-Resistance Mutations1
HIV 101 Continued on page 6
Table 1 continued on page 6
6meaning resistance is four-fold greater than that of the reference
strain. The newer method individualizes by drug. For the Virco
assay, the fold changes that define resistance are: zidovudine (AZT)
- 4.0, lamivudine (3TC) - 4.5, didanosine (ddI) - 3.5, zalcitabine (ddC)
- 3.5, stavudine (d4T) - 3.0, abacavir (ABC) - 3.0, nevirapine (NVP)
- 8.0, efavirenz (EFV) - 6.0, indinavir (IDV) - 3.0, ritonavir (RTV) - 3.5,
nelfinavir (NFV) - 4.0, saquinavir (SQV) - 2.5, amprenavir (APV) -2.5.
Virtual phenotypeis a prediction of the phenotype of the test strain
based on genotypic analysis. The mutational pattern of the test
strain is compared with results of phenotypic assay results with
strains showing similar mutations from a databank of >55,000 HIV
isolates.
Phenotypic assays include Phenosense and Phenosense GT (geno-
type and phenotype in one) (Virologic), Antivirogram and Virtual
Phenotype (Virco).
DISCLOSURES: 
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Update on HIV Resistance Testing...
(continued from page 4)
Understanding HIV Drug-Resistance Mutations (cont. from page 5)
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DRUG
Indinavir (IDV)
Nelfinavir (NFV)
Ritonavir (RTV)
Saquinivir (SQV)
Amprenavir (APV)
Lopinavir
(LPV)/RTV
(Kaletra)
PRIMARY^
46, 82
30, 90
82
48, 90
50, 84
____
SECONDARY^^
10,20,24,46, 63,64,82,84, 90
35,36,46,71, 88
8,10,20,33, 36,46,54,63,
71,84,90
10,24,30,46, 54,63,64,71,
73,77,81,84, 88
10,32,46,47, 54
10,20,24,46,53,63,71,82,84,
90
COMMENTS
At least 3 mutations required for resistance (>4x
decrease in susceptibility)
D30N most common mutation: no PI cross-resis
tance. L90M occurs in some, leading to greater PI
cross-resistance
Cross-resistance with IDV common
90 develops first, then 48; codon 48 mutation
unique but L90M confers PI cross-resistance
50 not associated with cross-resistance
Resistance correlated with number mutations.
Minimal data available on PI mutations following
LPV/RTV failure.
Table 1. Common Drug-Resistance Mutations1 (cont. from page 5)
PIs (Protease Inhibitors)
*Evolving data suggest cross-resistance between AZT and d4T and ABC ascribed to thymidine analog mutations (TAMs) intro-
duced by exposure to AZT or d4T.
The distinction between primary and secondary mutations has been eliminated for NRTIs and NNRTIs by the International AIDS
Society Expert Committee; the distinction has been retained for PIs.  
^Primary mutations: usually develop first, and are associated with decreased drug binding; 
^^Secondary mutations: also contribute to drug resistance and may affect drug binding in vitro less than primary mutations.
1 Table from Bartlett JG, Gallant JE, et al.  2001-2002 Medical Management of HIV Infection.  Johns Hopkins University, Division
of Infectious Diseases; 2001 (p.20).  On the web at http://hopkins-aids.edu.
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HIV-Positive Patient
Newly Diagnosed Patient
YES
Get a history of possible exposure;
find out source's HAART history if
possible.
Patient on Failing 
Treatment Regimen
Patient has had 
Interrupted Treatment*
Check adherence and reinforce as
necessary.
Get full drug history:
w HAART medication history
w Duration of treatment for 
each drug
w Side effect profile
w Patient preferences
Even though restarting may lead to
treatment failure, re-initiate most
recent previous regimen. Try to
avoid introducing new drugs until
success or failure is established. 
(See HEPPigram, HEPP News
February 2000; vol 3 Issue 2)
Follow up with HIV viral load (VL).
If patient fails to respond to 
treatment, genotype or 
phenotype.
If adherence is not the problem,
resistance may be developing.
Consider genotype or phenotype
while patient is ON treatment.
Discuss options with patient.
Review results; develop several
possible treatment regimens. 
If possible, obtain consultation with
HAART specialist to determine 
best possible regimen.
Does patient live in area where
drug-resistant virus is common?
(see Bennett, et al.  Abstract 372-
M, 9th CROI, February 25-28, 2002
Seattle, WA.)
Is patient documented recent 
seroconverter?
YES
Consider geno-
type or pheno-
type at initial
encounter - this
identifies base-
line resistance,
if present.
NO
No genotype or
phenotype 
recommended at
this time.
NO
No genotype or
phenotype 
recommended at
this time.
* "Unstructured" treatment interruption is very common in correctional settings,
due to cycles of release and re-incarceration
Also see HEPPigram, HEPP News, September 2000, vol. 3 issue 9.
Resources & Websites
Resistance Resources:
International AIDS Society-USA
http://www.iasusa.org/resistance_mutations/index.html
http://www.iasusa.org/resistance_mutations/revisedmutafigures-
11.30.01.pdf
HIV/Hepatitis Resources:
NIH Hepatitis Consensus meeting
Updates at http://consensus.nih.gov
Canadian HIV/AIDS Policy and Law Review(Latest issue)
Reviews: HIV/AIDS in prison, mother-to-child transmission, and com-
pulsory testing after occupational exposure http://www.aidslaw.ca/
Maincontent/otherdocs/Newsletter/newsletter.htm#ci
Hopkins HIV Report May 2002: Women and HIV
http://hopkins-aids.edu/publications/report/ may02_1.html
The Women's Caucus
http://www.thebody.com/bp/janfeb02/
womens_caucus.html
Big Shot: Passion, Politics, and the Struggle for an AIDS Vaccine
By Patricia Thomas, Review at
http://bmj.com/cgi/content/full/324/7339/743
amfAR HIV/AIDS Treatment Directory, 2002 Winter Edition
Free (incl. shipping); Large quantities available for clinical settings.
Contact Gretchen.Schmelz@amfar.org or call 212.806.1762
XIV International AIDS
Conference
July 7-12, 2002
Barcelona, Spain
Fee: After May 1: $1050 
(special rates and scholarships
available)
Visit: www.aids2002.com
Email: aids2002.registration@
congrex.se
HEPP News staff will be in 
attendance.
6th Annual United States
Conference on AIDS (USCA)
September 19-22, 2002
Anaheim, California
Fee: before 8/23- $375/$450
Visit: http://www.nmac.org/
usca2002/
Call: Paul Woods, 
202.483.6622 ext. 343
Email: pwoods@nmac.org
Management of HIV/AIDS in the
Correctional Setting:
"Occupational Exposure to
Viruses"
Satellite Videoconference
October 15, 2002; 
12:30-3:30 EST
CME & Nursing Credits Available
Visit: http://www.amc.edu/Patient/
HIV/hivconf.htm
Call: 518.262.4674
E-mail: ybarraj@mail.amc.edu
26th National Conference on
Correctional Health Care
October 19-23, 2002
Nashville, Tennessee
Visit: http://www.ncchc.org
Call: 773.880.1460
Email: ncchc@ncchc.org
North American AIDS
Treatment Action Forum
December 8-11, 2002
New Orleans, Louisiana
Visit: http://www.nmac.org/nataf/
2002/
Call: 202.483.6622
Save the 
Dates
8
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High Prevalence of HIV/AIDS Risk Behaviors
Among Incarcerated Women
Am J Public Health 2002;92:818-825
A new study of the Cook County Department of
Corrections system reveals that urban women
jailed for relatively minor infringements of the law
have a high prevalence of HIV/AIDS risk behav-
iors. Inmates with the highest risk behaviors
include Caucasian women, older women, those
with previous arrests, and those with severe
mental illness.  Additionally, sexual and drug use
risk scores were higher for women who had pre-
viously been arrested for prostitution, drug pos-
session, or theft than women who were arrested
for the first time. This study provides further sup-
port to the recommendation to provide HIV test-
ing to all inmates. 
Preliminary Results Show Tenofovir
Comparable to Stavudine in Treatment Naïve
Press Release, 5/7/02
Preliminary data from Gilead Science's 903
study has shown that tenofovir (TDF, Viread) and
stavudine (d4T, Zerit, Bristol Myers Squibb) have
comparable efficacy in treatment-naïve HIV-
positive patients. All 600 patients in this placebo-
controlled, double-blinded study are on
three-drug cocktails of either tenofovir/lamivu-
dine (3TC)/efavirenz or stavudine/lamivudine/
efavirenz. The data released from the 48-week
time point shows that 87% of patients in each
group achieved suppression of HIV viral load
below 400 copies/mL; 82% of patients in the
tenofovir arm of the study achieved viral load
suppression below 50 copies/mL compared with
81% of the patients in the stavudine arm of the
study. This preliminary data shows that tenofovir
is effective in treatment-naïve patients.  
New Protease Inhibitor in Development
Pipeline Now Available to Some Patients
www.natap.org, 5/21/02
Bristol-Myers Squibb has announced an early
access program (EAP) to provide atazanavir, a
new, experimental protease inhibitor to patients
who meet specified entry criteria. For more infor-
mation, call 1.877.7BMSEAP (1.877.726.7327).
60% of Monthly Releasees from South Africa
Prisons are HIV Positive
Agence France-Presse, 5/21/02
According to Judge Johannes Fagan, approxi-
mately 60% of the 10,000 inmates released from
South African prisons each month are HIV-posi
tive, based on a sample of 100 inmates. In his
presentation to the parliamentary correctional
services committee, Fagan also addressed the
overcrowding in the prisons, citing that over-
crowding is not conducive to the health of HIV-
positive inmates and contributes to the spread of
tuberculosis.
Results from Phase III Trial of T-20 Fusion
Inhibitor
Wall Street Journal, 4/19/02
T-20, a fusion inhibitor that works by blocking
HIV from fusing with and entering uninfected
cells, has shown encouraging results in its first
Phase III clinical trial. T-20 must be injected
twice a day.  Roche and Trimeris, who manufac-
ture the drug, plan to apply for FDA approval
later this year.
Viral Fitness Assay Now Available
Virologic Press Release, 6/3/02
Virologic has announced the availability of a new
assay that will measure the viral fitness, or repli-
cation capacity, of HIV. This Replication Capacity
(RC) assay measures the ability of a patient¹s
virus to make copies of itself and may be useful
in guiding HIC treatment strategy. The RC assay
will be included in combination with the compa-
ny’s Phenosense HIV and Phenosense GT
assays that measure HIV-drug resistance (see
Main Article for a discussion of drug-resistance).
HEPATITIS
NIH Consensus Panel Addresses HCV in
Corrections
http://www.nih.gov/news/pr/jun2002/od-12.htm
Hepatitis treatment guidelines were addressed
at the NIH Hepatitis Consensus Meeting June
10-12, 2002. The NIH Hepatitis Consensus
Panel states: "Because a large number of HCV-
infected persons in the United States are incar-
cerated, strategies should be developed to better
prevent, diagnose, and treat these individuals."
The full text of the panel's statement will be avail-
able in draft form at http://consensus.nih.gov. A
summary of the hepatitis C evidence report pre-
pared by the Johns Hopkins University School of
Medicine is available at http://www.ahrq.gov/clin-
ic/epcix.htm. Copies are also available by calling
1-800-358-9295.
Common Household Items May Transmit HCV
Reuters Health, 5/22/02
A new study presented at Digestive Disease
Week, common household items, including
toothbrushes, may present an avenue of HCV
transmission.The study looked at 30 HCV-infect-
ed patients, and examined their saliva and their
toothbrushes for the presence of HCV infection.
Approximately 40% of the toothbrushes tested
positive for HCV, along with 30% of saliva sam-
ples collected before tooth-brushing and 38% of
samples collected after tooth-brushing. These
results did not seem to be tied to oral hygiene or
disease severity. Although it is not known
whether the virus found on the toothbrushes
could be used to infect another individual,
experts say this is "not impossible." Study
authors urge HCV-positive individuals not to
share these sorts of household items. 
Chowchilla Prison Suit Settled Pre-Trial
Fresno Bee, 6/14/02
A lawsuit alleging medical neglect that led to the
death of an inmate at California’s Chowchilla
women’s facility has been settled out of court for
$225,000. The inmate died in 1999 and was
infected with hepatitis C. According to accounts
of the case, the inmate had told medical person-
nel in the prison that she was infected with HCV,
but was placed in an aggressive TB treatment
program and given medications that are known
to be toxic to people with liver disease.  The
inmate did not have access to a liver disease
expert until a few days prior to her death.
Inside News
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through January 31, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. In the Richman, et al. study, what percentage of patients on
treatment with viral loads >500 copies/mL had resistance to at
least one antiretroviral (ARV) agent?
a) 14%
b) 23%
c) 56%
d) 78%
e) 92%
2. Resistance is not an all or none phenomenon.
a) True
b) False
3. A patient was on lamivudine as part of her HAART regimen and
developed resistance to the drug.  Her drug regimen was therefore
changed completely.  Two years later, the same patient undergoes
resistance testing.  The new data does not show a resistance to
lamivudine.  If the patient is restarted on lamivudine, would you
expect viral replication to be suppressed? Why or Why not?
a) Yes; the patient is no longer harboring lamivudine-
resistant virus
b) Yes; the patient has not "seen" the drug in two years
c) No; the patient is still harboring lamivudine-resistant virus, 
but not in large enough amounts to be picked up by the 
resistance testing
d) No; once a patient is taken off a drug for any reason, s/he 
will not be able to respond to it again
e) It is impossible to hypothesize
4. Resistance test results shows a G190A mutations in the reverse
transcriptase gene. What does G190A mean, and which drugs
might it confer resistance to?
a) A glutamine at position 190 in wild-type reverse transcriptase 
has mutated to an alanine; virus might be resistant to nevirapine
b) A glutamic acid at position 190 in wild-type reverse transcrip-
tase has mutated to an arginine; virus might be resistant to 
nevirapine and efavirenz
c) An alanine at position 190 in wild-type reverse transcriptase 
has mutated to an glycine; virus might be resistant to nevirapine 
and efavirenz
d) A glycine at position 190 in wild-type reverse transcriptase 
has mutated to an alanine; virus might be resistant to nevirapine 
and efavirenz 
e) A glycine at position 190 in wild-type protease has mutated to 
an aspartic acid; virus might be resistant to efavirenz
5. Which of the following statements is (are) true?
a) Sequential changes in antiretroviral agents (rather than 
changing the entire regime at once) will lead to incomplete 
suppression.
b) Viral evolution and mutation accumulation will occur in the 
setting of incomplete viral suppression (even with clinical and 
immunologic stability)
c) In order to interpret genotypic test results, a certain level of 
knowledge and expertise of drug-resistance mutations is 
required
d) a and c
e) a, b, and c
6. If a patient seems to be failing his drug regimen, and it is deter-
mined that the patients needs to be genotyped or phenotyped,
when should the test occur?
a) While the patient is still adhering to his current HAART 
regimen
b) After the patient has been off HAART therapy for two weeks
c) After the patient has been off of HAART therapy for 1 month
d) Two weeks after the patient begins a new HAART regimen
e) The test should only be done if the patient has been on the 
same HAART regimen for longer than 1 year
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
5. Do you have specific comments on this issue?
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